Serum vascular endothelial growth factor and adiponectin levels in patients with benign and malignant gynecological diseases

Carla Lasalandra, Maria Coviello, Gaetano Falco, Rosa Divella, Giuseppe Trojano, Anna Maria Laterza, Carmela Quero, Vito Pepe, Francesco Alfredo Zito, Michele Quaranta

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: One of the most specific and critical regulators of angiogenesis is vascular endothelial growth factor (VEGF), which regulates endothelial proliferation, permeability, and survival. Vascular endothelial growth factor is an angiogenic mediator in tumors and has been implicated in the pathogenesis and progression of cancer. Adipose tissue is a major endocrine and it secretes hormones termed adipokines. These factors are derived from adipocytes and include proteins and metabolites such as adiponectin. Recently, adiponectin was also shown to modulate angiogenesis. This study was designed to determine the serum VEGF and adiponectin levels in patients with benign and malignant gynecological diseases and if there was a correlation between serum VEGF and adiponectin. Methods: Serum samples, collected fasting before surgery or intervention, were available for total of 114 female patients recorded between October 2006 and December 2008. Diagnosis of benign and malignant gynaecological diseases was established by biopsy. Serum levels VEGF and adiponectin were using commercially available enzyme linked immunosorbent assay (R&D Systems Inc, Minneapolis, MN), respectively. Statistical analysis was performed by using the SPSS 9.0 software package (SPSS, Inc, Chicago, IL). The correlation between serum VEGF and serum Adiponectin was calculated using the Pearson correlation coefficient. P values of <0.05 were considered statistically significant. Results: Our results were analyzed on the basis of 2 different parameters: age and benign and malignant gynecological diseases of the patient. Only for serum VEGF levels was a significant difference observed (P = 0.004) between patients with benign and malignant gynecological diseases. A significantly inverse correlation between serum VEGF and adiponectin levels among patients with benign and malignant gynecological diseases was found. Adiponectin level is not correlated with body mass index. Conclusions: This is one of the first report on adiponectin in benign and malignant gynecological diseases. Future studies are needed to address the clinical potential role of adipo-nectin in cancer.

Original languageEnglish
Pages (from-to)507-512
Number of pages6
JournalInternational Journal of Gynecological Cancer
Volume20
Issue number4
DOIs
Publication statusPublished - May 2010

Fingerprint

Adiponectin
Vascular Endothelial Growth Factor A
Serum
Neoplasms
Adipokines
Adipocytes
Adipose Tissue
Permeability
Fasting
Body Mass Index
Software
Enzyme-Linked Immunosorbent Assay
Hormones
Biopsy
Survival

Keywords

  • Adiponectin
  • Angiogenesis
  • Gynecological disease
  • VEGF

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Serum vascular endothelial growth factor and adiponectin levels in patients with benign and malignant gynecological diseases. / Lasalandra, Carla; Coviello, Maria; Falco, Gaetano; Divella, Rosa; Trojano, Giuseppe; Laterza, Anna Maria; Quero, Carmela; Pepe, Vito; Zito, Francesco Alfredo; Quaranta, Michele.

In: International Journal of Gynecological Cancer, Vol. 20, No. 4, 05.2010, p. 507-512.

Research output: Contribution to journalArticle

Lasalandra, C, Coviello, M, Falco, G, Divella, R, Trojano, G, Laterza, AM, Quero, C, Pepe, V, Zito, FA & Quaranta, M 2010, 'Serum vascular endothelial growth factor and adiponectin levels in patients with benign and malignant gynecological diseases', International Journal of Gynecological Cancer, vol. 20, no. 4, pp. 507-512. https://doi.org/10.1111/IGC.0b013e3181c54fc5
Lasalandra, Carla ; Coviello, Maria ; Falco, Gaetano ; Divella, Rosa ; Trojano, Giuseppe ; Laterza, Anna Maria ; Quero, Carmela ; Pepe, Vito ; Zito, Francesco Alfredo ; Quaranta, Michele. / Serum vascular endothelial growth factor and adiponectin levels in patients with benign and malignant gynecological diseases. In: International Journal of Gynecological Cancer. 2010 ; Vol. 20, No. 4. pp. 507-512.
@article{08d76e46b2cf4fb3a1cc3a90528b8b2d,
title = "Serum vascular endothelial growth factor and adiponectin levels in patients with benign and malignant gynecological diseases",
abstract = "Introduction: One of the most specific and critical regulators of angiogenesis is vascular endothelial growth factor (VEGF), which regulates endothelial proliferation, permeability, and survival. Vascular endothelial growth factor is an angiogenic mediator in tumors and has been implicated in the pathogenesis and progression of cancer. Adipose tissue is a major endocrine and it secretes hormones termed adipokines. These factors are derived from adipocytes and include proteins and metabolites such as adiponectin. Recently, adiponectin was also shown to modulate angiogenesis. This study was designed to determine the serum VEGF and adiponectin levels in patients with benign and malignant gynecological diseases and if there was a correlation between serum VEGF and adiponectin. Methods: Serum samples, collected fasting before surgery or intervention, were available for total of 114 female patients recorded between October 2006 and December 2008. Diagnosis of benign and malignant gynaecological diseases was established by biopsy. Serum levels VEGF and adiponectin were using commercially available enzyme linked immunosorbent assay (R&D Systems Inc, Minneapolis, MN), respectively. Statistical analysis was performed by using the SPSS 9.0 software package (SPSS, Inc, Chicago, IL). The correlation between serum VEGF and serum Adiponectin was calculated using the Pearson correlation coefficient. P values of <0.05 were considered statistically significant. Results: Our results were analyzed on the basis of 2 different parameters: age and benign and malignant gynecological diseases of the patient. Only for serum VEGF levels was a significant difference observed (P = 0.004) between patients with benign and malignant gynecological diseases. A significantly inverse correlation between serum VEGF and adiponectin levels among patients with benign and malignant gynecological diseases was found. Adiponectin level is not correlated with body mass index. Conclusions: This is one of the first report on adiponectin in benign and malignant gynecological diseases. Future studies are needed to address the clinical potential role of adipo-nectin in cancer.",
keywords = "Adiponectin, Angiogenesis, Gynecological disease, VEGF",
author = "Carla Lasalandra and Maria Coviello and Gaetano Falco and Rosa Divella and Giuseppe Trojano and Laterza, {Anna Maria} and Carmela Quero and Vito Pepe and Zito, {Francesco Alfredo} and Michele Quaranta",
year = "2010",
month = "5",
doi = "10.1111/IGC.0b013e3181c54fc5",
language = "English",
volume = "20",
pages = "507--512",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Serum vascular endothelial growth factor and adiponectin levels in patients with benign and malignant gynecological diseases

AU - Lasalandra, Carla

AU - Coviello, Maria

AU - Falco, Gaetano

AU - Divella, Rosa

AU - Trojano, Giuseppe

AU - Laterza, Anna Maria

AU - Quero, Carmela

AU - Pepe, Vito

AU - Zito, Francesco Alfredo

AU - Quaranta, Michele

PY - 2010/5

Y1 - 2010/5

N2 - Introduction: One of the most specific and critical regulators of angiogenesis is vascular endothelial growth factor (VEGF), which regulates endothelial proliferation, permeability, and survival. Vascular endothelial growth factor is an angiogenic mediator in tumors and has been implicated in the pathogenesis and progression of cancer. Adipose tissue is a major endocrine and it secretes hormones termed adipokines. These factors are derived from adipocytes and include proteins and metabolites such as adiponectin. Recently, adiponectin was also shown to modulate angiogenesis. This study was designed to determine the serum VEGF and adiponectin levels in patients with benign and malignant gynecological diseases and if there was a correlation between serum VEGF and adiponectin. Methods: Serum samples, collected fasting before surgery or intervention, were available for total of 114 female patients recorded between October 2006 and December 2008. Diagnosis of benign and malignant gynaecological diseases was established by biopsy. Serum levels VEGF and adiponectin were using commercially available enzyme linked immunosorbent assay (R&D Systems Inc, Minneapolis, MN), respectively. Statistical analysis was performed by using the SPSS 9.0 software package (SPSS, Inc, Chicago, IL). The correlation between serum VEGF and serum Adiponectin was calculated using the Pearson correlation coefficient. P values of <0.05 were considered statistically significant. Results: Our results were analyzed on the basis of 2 different parameters: age and benign and malignant gynecological diseases of the patient. Only for serum VEGF levels was a significant difference observed (P = 0.004) between patients with benign and malignant gynecological diseases. A significantly inverse correlation between serum VEGF and adiponectin levels among patients with benign and malignant gynecological diseases was found. Adiponectin level is not correlated with body mass index. Conclusions: This is one of the first report on adiponectin in benign and malignant gynecological diseases. Future studies are needed to address the clinical potential role of adipo-nectin in cancer.

AB - Introduction: One of the most specific and critical regulators of angiogenesis is vascular endothelial growth factor (VEGF), which regulates endothelial proliferation, permeability, and survival. Vascular endothelial growth factor is an angiogenic mediator in tumors and has been implicated in the pathogenesis and progression of cancer. Adipose tissue is a major endocrine and it secretes hormones termed adipokines. These factors are derived from adipocytes and include proteins and metabolites such as adiponectin. Recently, adiponectin was also shown to modulate angiogenesis. This study was designed to determine the serum VEGF and adiponectin levels in patients with benign and malignant gynecological diseases and if there was a correlation between serum VEGF and adiponectin. Methods: Serum samples, collected fasting before surgery or intervention, were available for total of 114 female patients recorded between October 2006 and December 2008. Diagnosis of benign and malignant gynaecological diseases was established by biopsy. Serum levels VEGF and adiponectin were using commercially available enzyme linked immunosorbent assay (R&D Systems Inc, Minneapolis, MN), respectively. Statistical analysis was performed by using the SPSS 9.0 software package (SPSS, Inc, Chicago, IL). The correlation between serum VEGF and serum Adiponectin was calculated using the Pearson correlation coefficient. P values of <0.05 were considered statistically significant. Results: Our results were analyzed on the basis of 2 different parameters: age and benign and malignant gynecological diseases of the patient. Only for serum VEGF levels was a significant difference observed (P = 0.004) between patients with benign and malignant gynecological diseases. A significantly inverse correlation between serum VEGF and adiponectin levels among patients with benign and malignant gynecological diseases was found. Adiponectin level is not correlated with body mass index. Conclusions: This is one of the first report on adiponectin in benign and malignant gynecological diseases. Future studies are needed to address the clinical potential role of adipo-nectin in cancer.

KW - Adiponectin

KW - Angiogenesis

KW - Gynecological disease

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=77952259410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952259410&partnerID=8YFLogxK

U2 - 10.1111/IGC.0b013e3181c54fc5

DO - 10.1111/IGC.0b013e3181c54fc5

M3 - Article

C2 - 20442584

AN - SCOPUS:77952259410

VL - 20

SP - 507

EP - 512

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 4

ER -